The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
The number of patients with chronic heart failure syndrome is steadily increasing worldwide and Ukraine is not an exception. About 50 % of patients with heart failure have preserved ejection fraction of left ventricle. Recently, there has been significant progress in the diagnosis of this phenotype...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine
2024-03-01
|
| Series: | Сучасні медичні технології |
| Subjects: | |
| Online Access: | https://medtech.mphu.edu.ua/article/view/296545/292789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846155229448372224 |
|---|---|
| author | M. Yu. Kolesnyk Ya. Yu. Maistrovych |
| author_facet | M. Yu. Kolesnyk Ya. Yu. Maistrovych |
| author_sort | M. Yu. Kolesnyk |
| collection | DOAJ |
| description | The number of patients with chronic heart failure syndrome is steadily increasing worldwide and Ukraine is not an exception. About 50 % of patients with heart failure have preserved ejection fraction of left ventricle. Recently, there has been significant progress in the diagnosis of this phenotype of heart failure, many diagnostic scales and practice-oriented algorithms have been developed, but the issue of treatment of chronic heart failure remains open.
Aim of the study. To summarize and analyze the results of large-scale randomized trials and to discuss the possible pathophysiological mechanisms underlying the “pleiotropiс” effects of sodium-glucose cotransporter-2 inhibitors.
Sodium-glucose cotransporter-2 inhibitors are the first class of antidiabetic drugs that have demonstrated improved cardiovascular prognosis in patients with chronic heart failure with preserved ejection fraction regardless of the presence of diabetes mellitus.
Conclusions. The necessity of prescribing sodium-glucose cotransporter-2 inhibitors in a cohort of patients with heart failure, regardless of left ventricular ejection fraction, has the highest level of evidence. The pathophysiological mechanisms underlying these effects are not fully understood. Further trials will allow us to identify new mechanisms of action and establish potential relationships between them. |
| format | Article |
| id | doaj-art-f4dc4852b60f41b4a1f549e4fd73f7c5 |
| institution | Kabale University |
| issn | 2072-9367 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine |
| record_format | Article |
| series | Сучасні медичні технології |
| spelling | doaj-art-f4dc4852b60f41b4a1f549e4fd73f7c52024-11-26T13:44:12ZengZaporizhia Medical Academy of Post-Graduate Education Ministry of Health of UkraineСучасні медичні технології2072-93672024-03-011616067https://doi.org/10.14739/mmt.2024.1.296545The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failureM. Yu. Kolesnyk0https://orcid.org/0000-0001-7566-1899Ya. Yu. Maistrovych1https://orcid.org/0000-0001-9005-2864Zaporizhzhia State Medical and Pharmaceutical University, Ukraine, UkraineZaporizhzhia State Medical and Pharmaceutical University, Ukraine, UkraineThe number of patients with chronic heart failure syndrome is steadily increasing worldwide and Ukraine is not an exception. About 50 % of patients with heart failure have preserved ejection fraction of left ventricle. Recently, there has been significant progress in the diagnosis of this phenotype of heart failure, many diagnostic scales and practice-oriented algorithms have been developed, but the issue of treatment of chronic heart failure remains open. Aim of the study. To summarize and analyze the results of large-scale randomized trials and to discuss the possible pathophysiological mechanisms underlying the “pleiotropiс” effects of sodium-glucose cotransporter-2 inhibitors. Sodium-glucose cotransporter-2 inhibitors are the first class of antidiabetic drugs that have demonstrated improved cardiovascular prognosis in patients with chronic heart failure with preserved ejection fraction regardless of the presence of diabetes mellitus. Conclusions. The necessity of prescribing sodium-glucose cotransporter-2 inhibitors in a cohort of patients with heart failure, regardless of left ventricular ejection fraction, has the highest level of evidence. The pathophysiological mechanisms underlying these effects are not fully understood. Further trials will allow us to identify new mechanisms of action and establish potential relationships between them.https://medtech.mphu.edu.ua/article/view/296545/292789sodium-glucose cotransporter-2 inhibitorscongestive heart failureinhibitors |
| spellingShingle | M. Yu. Kolesnyk Ya. Yu. Maistrovych The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure Сучасні медичні технології sodium-glucose cotransporter-2 inhibitors congestive heart failure inhibitors |
| title | The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| title_full | The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| title_fullStr | The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| title_full_unstemmed | The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| title_short | The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| title_sort | role of sodium glucose cotransporter 2 inhibitors in the treatment of different phenotypes of chronic heart failure |
| topic | sodium-glucose cotransporter-2 inhibitors congestive heart failure inhibitors |
| url | https://medtech.mphu.edu.ua/article/view/296545/292789 |
| work_keys_str_mv | AT myukolesnyk theroleofsodiumglucosecotransporter2inhibitorsinthetreatmentofdifferentphenotypesofchronicheartfailure AT yayumaistrovych theroleofsodiumglucosecotransporter2inhibitorsinthetreatmentofdifferentphenotypesofchronicheartfailure AT myukolesnyk roleofsodiumglucosecotransporter2inhibitorsinthetreatmentofdifferentphenotypesofchronicheartfailure AT yayumaistrovych roleofsodiumglucosecotransporter2inhibitorsinthetreatmentofdifferentphenotypesofchronicheartfailure |